1 Picture That Sums Up Moderna's Biggest Problem
You might think that investors would love Moderna (NASDAQ: MRNA) based on its business performance. The company reported $4.7 billion in revenue for the second quarter of 2022. Nearly half of that amount -- $2.2 billion -- was profit.
Moderna's cash position topped $18 billion at the end of Q2. It's on track to sell $21 billion of its COVID-19 vaccines this year. The company also continues to pick up authorizations and approvals across the world for its new vaccine targeting the coronavirus omicron variant.
But all isn't well for the vaccine leader. Here's one picture that sums up Moderna's biggest problem:
Source Fool.com
